Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double‐blind, 8‐week study

Cheung, Deanna G.; Aizenberg, Diego; Горбунов, В. М.; Hafeez, Kudsia; Chen, Chien‐Wei; Zhang, Jack

doi:10.1111/jch.13153

Cited by 56 publications

(63 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Сакубитрил/валсартан показва превъзходство по отношение на понижаване както на 24 часа амбулаторно измереното систолно АН, така и на офисното систолно АН от изходното за срок от 8 седмици в сравнение с олмесартан. Честотата на странични нежелани ефекти е сходна в двете групи с преобладване основно на главоболие и главозамайване [15]. Проучването на Supasyndh и кол.…”

Section: An Antihypertensive Eff Ect Of Sacubitril/ Valsartan (Entresto)unclassified

Novel approaches to treat resistant hypertension

Cherneva¹,

Petrov²

2020

Bulgarian Cardiology

View full text Add to dashboard Cite

Treatment-resistant hypertension, or resistant hypertension (RH), is defined as arterial hypertension (AH) despite treatment with three properly dosed antihypertensive drugs, at least one of which is a diuretic. Resistant hypertension is associated with an increased incidence of adverse cardiovascular events, renal impairment, and increased mortality. The main treatment of patients with RH is based on maximizing doses of antihypertensive drugs from different groups and adding drugs with complementary mechanisms of action. Despite the combination treatment involving multiple antihypertensive drugs, a small but significant group of patients remains with uncontrolled hypertension, emphasizing the need to find and put into practice new therapies to lower high arterial blood pressure (BP). Among these new methods of treatment, the most promising is the renal sympathetic denervation, showing positive results with the second generation devices. This review summarizes current knowledge about the treatment of RH, with an emphasis on new therapeutic strategies to achieve optimal blood pressure control.

show abstract

Section: An Antihypertensive Eff Ect Of Sacubitril/ Valsartan (Entresto)unclassified

Novel approaches to treat resistant hypertension

Cherneva¹,

Petrov²

2020

Bulgarian Cardiology

View full text Add to dashboard Cite

show abstract

“…Numerous studies have demonstrated beneficial effects of sacubitril/valsartan on BP in patients without HF who have HTN ( Table 1 ). 11 – 21 The BP lowering effects of sacubitril/valsartan in patients with HTN has been evaluated both alone and in combination with other antihypertensive agents. The most recently published study on this topic by Cheung and colleagues evaluated 376 patients (mean age at baseline 57.6 years old) with an SBP ≥145 mmHg and <180 mmHg (mean baseline SBP was 157.5±9.85 mmHg and mean baseline 24-hour ambulatory SBP was 139.1±14.30 mmHg) who received either sacubitril/valsartan 200 mg orally once daily or olmesartan 20 mg orally once daily.…”

Section: Safety and Efficacy Of Blood Pressure Lowering With Sacubitrmentioning

confidence: 99%

“…Adverse event rates between groups were similar (23.4 versus 21.9%, respectively), with headache and dizziness being those most commonly reported. 11 A similar study by Supasyndh et al also evaluated the BP-lowering effects of sacubitril/valsartan 200 mg orally once daily (N=296) compared with olmesartan 20 mg orally once daily (N=292) over 14 weeks, albeit in an older population (mean age at baseline 70.7 years old). At week 10 of 14, patients with BP >140/90 mmHg had their antihypertensive doses up-titrated to sacubitril/valsartan 400 mg orally daily or olmesartan 40 mg orally daily, respectively.…”

Section: Safety and Efficacy Of Blood Pressure Lowering With Sacubitrmentioning

confidence: 99%

“…Hypotension was either reported at an incidence of 1 to 2% or not reported at all. 11 – 21 This is likely because the patients in the sacubitril/valsartan HF studies typically had lower baseline BP values than those enrolled in the sacubitril/valsartan HTN studies and the treatment doses for HF were twice daily as opposed to once daily for HTN.…”

Section: Safety and Efficacy Of Blood Pressure Lowering With Sacubitrmentioning

confidence: 99%

See 1 more Smart Citation

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment

Anderson¹,

Marrs²

2018

DIC

View full text Add to dashboard Cite

Hypertension (HTN) is a common disease state associated with extensive morbidity and mortality worldwide. It is often difficult for patients with HTN to achieve and maintain a goal blood pressure (BP), despite there being many effective treatment options available. Sacubitril/valsartan is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) that has garnered approval by the US Food and Drug Administration and the European Medicines Agency as a first-line treatment for heart failure with reduced ejection fraction. During clinical trials for heart failure as well as in independent trials for HTN, sacubitril/valsartan has demonstrated safety and efficacy when it comes to BP lowering, making it a promising antihypertensive agent. Most trials of sacubitril/valsartan were 8 to 12 weeks in length and demonstrated a clinically relevant BP lowering that was frequently more significant than its comparators. While more data are needed to confirm its role as an antihypertensive agent, the data available are promising and it is anticipated that sacubitril/valsartan will gain an indication of HTN.

show abstract

“…However, this feature of sacubitril/valsartan may be an advantage in the treatment of hypertension. Compatible with this view, several studies investigated the potential of sacubitril/valsartan in hypertension treatment and found positive results ( 131 - 133 ). Sacubitril/valsartan decreased BP significantly and was found to be superior compared to ARBs, especially in elderly patients with arterial stiffness ( 133 , 134 ).…”

Section: Introductionmentioning

confidence: 99%